Cytochrome P450 interactions in human cancers: New aspects considering CYP1B1

Expert Opinion on Drug Metabolism and Toxicology

Volumn 1, Issue 2, 2005, Pages 187-202

  Roos, Peter H ^a   Bolt, Hermann M ^a  

^a LEIBNIZ RESEARCH CENTRE FOR WORKING ENVIRONMENT AND HUMAN FACTORS   (Germany)

Author keywords

breast cancer; CYP; CYP1B1; head and neck cancer; lung cancer; urothelial cancer

Indexed keywords

CYTOCHROME P 450 CYP1B1; CYTOCHROME P-450 CYP1B1; CYTOCHROME P450; UNSPECIFIC MONOOXYGENASE;

ANIMAL; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; NEOPLASM; REVIEW;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; NEOPLASMS;

EID: 33646270828     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.1.2.187     Document Type: Review

References (130)

1. RODIN SN, RODIN AS: Origins and selection of p53 mutations in lung carcinogenesis. Semin. Cancer Biol. (2005) 15:103-112. (Pubitemid 40126241)
2. HUYNH H: Overexpression of tumour suppressor retinoblastoma 2 protein (pRb2/ p130) in hepatocellular carcinoma. Carcinogenesis (2004) 25:1485-1494. (Pubitemid 39172079)
3. KIM WY, KAELIN WG: Role of VHL gene mutation in human cancer. J. Clin. Oncol. (2004) 22:4991-5004. (Pubitemid 46646218)
4. MILLER F, KENTSIS A, OSMAN R, PAN ZQ: Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL: HIF- 1alpha complex. J. Biol. Chem. (2005) 280:7986-7996.
5. THIER R, GOLKA K, BRÜNING T, KO Y, BOLT HM: Genetic susceptibility to environmental toxicants: the interface between human and experimental studies in the development of new toxicological concepts. Toxicol. Lett. (2002) 127(1-3):321-327. (Pubitemid 34615524)
6. CHARLOUX A, QUOIX E, WOLKOVE N, SMALL D, PAULI G, KREISMAN H: The increasing incidence of lung adenocarcinoma: reality or artefact? A review of the epidemiology of lung adenocarcinoma. Int. J. Epidemiol. (1997) 26:14-23. (Pubitemid 27129564)
7. JANSSEN-HEIJNEN ML, COEBERGH JW: The changing epidemiology of lung cancer in Europe. Lung Cancer (2003) 41:245-258. (Pubitemid 36970181)
8. DE LAS HERAS M, GONZALEZ L, SHARP JM: Pathology of ovine pulmonary adenocarcinoma. Curr. Top. Microbiol. Immunol. (2003) 275:25-54. (Pubitemid 36025493)
9. OGHISO Y, YAMADA Y: Immunohistochemical study on cellular origins of at lung tumors induced by inhalation exposures to plutonium dioxide aerosols as compared to those by X-ray irradiation. J. Radiat. Res. (2002) 43:301-311. (Pubitemid 135691185)
10. NISHIMURA M, YAGUTI H, YOSHITSUGU H, NAITO S, SATOH T: Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi (2003) 123:369-375. (Pubitemid 41327466)
11. DING X, KAMINSKY LS: Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu. Rev. Pharmacol. Toxicol. (2003) 43:149-173. (Pubitemid 37372638)
12. PETERSON LA, HECHT SS: O6- methylguanine is a critical determinant of 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone tumorigenesis in A/J mouse lung. Cancer Res. (1991) 51:5557-5564.
13. WANG H, TAN W, HAO B et al.: Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK. Cancer Res. (2003) 63:8057-8061. (Pubitemid 37466745)
14. BELINSKY SA, WHITE CM, DEVEREUX TR, SWENBERG JA, ANDERSON MW: Cell selective alkylation of DNA in rat lung following low dose exposure to the tobacco specific carcinogen 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)- 1-butanone. Cancer Res. (1987) 47:1143-1148. (Pubitemid 17027943)
15. RIOUX N, CASTONGUAY A: Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res. (1998) 58:5354-5360. (Pubitemid 28551116)
16. HARRIS RE, BEEBE-DONK J, SCHULLER HM: Chemoprevention of lung cancer by non-steroidal antiinflammatory drugs among cigarette smokers. Oncol. Rep. (2002) 9:693-695.
17. CAMPA D, ZIENOLDDINY S, MAGGINI V, SKAUG V, HAUGEN A, CANZIAN F: Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis (2004) 25:229-235. (Pubitemid 38239806)
18. DEVANESAN PD, CREMONESI P, NUNNALLY JE, ROGAN EG, CAVALIERI EL: Metabolism and mutagenicity of dibenzo[a,e]pyrene and the very potent environmental carcinogen dibenzo[a,l]pyrene. Chem. Res. Toxicol. (1990) 3:580-586.
19. PIIPARI R, SAVELA K, NURMINEN T et al.: Expression of CYP1A1, CYP1B1 and CYP3A, and polycyclic aromatic hydrocarbon-DNA adduct formation in bronchoalveolar macrophages of smokers and non-smokers. Int. J. Cancer (2000) 86:610-616. (Pubitemid 30249869)
20. ROSS JA, NELSON GB, WILSON KH et al.: Adenomas induced by polycyclic aromatic hydrocarbons in strain A/J mouse lung correlate with time-integrated DNA adduct levels. Cancer Res. (1995) 55:1039-1044.
21. DENISSENKO MF, PAO A, TANG M, PFEIFER GP: Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in p53. Science (1996) 274:430-432. (Pubitemid 26353359)
22. WESTRA WH, OFFERHAUS GJ, GOODMAN SN et al.: Overexpression of the p53 tumor suppressor gene product in primary lung adenocarcinomas is associated with cigarette smoking. Am. J. Surg. Pathol. (1993) 17:213-220. (Pubitemid 23085915)
23. WARREN AJ, SHIELDS PG: Molecular epidemiology: carcinogen-DNA adducts and genetic susceptibility. Proc. Soc. Exp. Biol. Med. (1997) 216:172-180.
24. HOULSTON RS: CYP1A1 polymorphisms and lung cancer risk: a meta-analysis. Pharmacogenetics (2000) 10:105-114. (Pubitemid 30193072)
25. DRESLER CM, FRATELLI C, BABB J, EVERLEY L, EVANS AA, CLAPPER ML: Gender differences in genetic susceptibility for lung cancer. Lung Cancer (2000) 30:153-160. (Pubitemid 32007871)
26. SATO M, SATO T, IZUMO T, AMAGASA T: Genetically high susceptibility to oral squamous cell carcinoma in terms of combined genotyping of CYP1A1 and GSTM1 genes. Oral Oncol. (2000) 36:267-271. (Pubitemid 30227708)
27. NAIR U, BARTSCH H: Metabolic polymorphisms as susceptibility markers for lung and oral cavity cancer. IARC Sci. Publ. (2001) 154:271-290.
28. QUINONES L, LUCAS D, GODOY J et al.: CYP1A1, CYP2E1 and GSTM1 genetic polymorphisms. The effect of single and combined genotypes on lung cancer susceptibility in Chilean people. Cancer Lett. (2001) 174:35-44. (Pubitemid 33001306)
29. BARTSCH H, NAIR U, RISCH A, ROJAS M, WIKMAN H, ALEXANDROV K: Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol. Biomarkers Prev. (2000) 9:3-28. (Pubitemid 30062906)
30. HOULSTON RS: Glutathione Stransferase M1 status and lung cancer risk: a meta-analysis. Cancer Epidemiol. Biomarkers Prev. (1999) 8:675-682. (Pubitemid 30064535)
31. WATANABE J, SHIMADA T, GILLAM EM et al.: Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer. Pharmacogenetics (2000) 10:25-33. (Pubitemid 30142810)
32. SPIVACK SD, HURTEAU GJ, FASCO MJ, KAMINSKY LS: Phase I and II carcinogen metabolism gene expression in human lung tissue and tumors. Clin. Cancer Res. (2003) 9:6002-6011. (Pubitemid 38018087)
33. SHIMADA T, MARTIN MV, PRUESS-SCHWARTZ D, MARNETT LJ, GUENGERICH FP: Roles of individual human cytochrome P450 enzymes in the bioactivation of benzo(a)pyrene, 7,8-dihydroxy-7,8-dihydrobenzo(a)pyrene, and other dihydrodiol derivatives of polycyclic aromatic hydrocarbons. Cancer Res. (1989) 49:6304-6312. (Pubitemid 20000928)
34. DALLY H, EDLER L, JAGER B et al.: The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose. Pharmacogenetics (2003) 13:607-618. (Pubitemid 37311147)
35. YEH KT, CHEN JC, CHEN CM, WANG YF, LEE TP, CHANG JG: CYP3A5*1 is an inhibitory factor for lung cancer in Taiwanese. Kaohsiung J. Med. Sci. (2003) 19:201-207.
36. NISHIMURA M, NAITO S, YOKOI T: Tissue-specific mRNA expression profiles of human nuclear receptor subfamilies. Drug Metab. Pharmacokinet. (2004) 19:135-149.
37. SOBTI RC, SHARMA S, JOSHI A, JINDAL SK, JANMEJA A: CYP1A1 and CYP2D6 polymorphism and risk of lung cancer in a North Indian population. Biomarkers (2003) 8:415-428. (Pubitemid 37509174)
38. LAFOREST L, WIKMAN H, BENHAMOU S et al.: CYP2D6 gene polymorphism in Caucasian smokers: lung cancer susceptibility and phenotypegenotype relationships. Eur. J. Cancer (2000) 36:1825-1832. (Pubitemid 30639503)
39. ROSTAMI-HODJEGAN A, LENNARD MS, WOODS HF, TUCKER GT: Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinsons disease. Pharmacogenetics (1998) 8:227-238. (Pubitemid 28282879)
40. CRESPI CL, PENMAN BW, GELBOIN HV, GONZALEZ FJ: A tobacco smoke-derived nitrosamine, 4- (methylnitrosamino)-1-(3-pyridyl)-1- butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6. Carcinogenesis (1991) 12:1197-201.
41. PENMAN BW, REECE J, SMITH T et al.: Characterization of a human cell line expressing high levels of cDNA-derived CYP2D6. Pharmacogenetics (1993) 3:28-39. (Pubitemid 23068383)
42. FUJITA K, KAMATAKI T: Predicting the mutagenicity of tobacco-related Nnitrosamines in humans using 11 strains of Salmonella typhimurium YG7108, each coexpressing a form of human cytochrome P450 along with NADPH-cytochrome P450 reductase. Environ. Mol. Mutagen. (2001) 38:339-346. (Pubitemid 34052170)
43. ABDEL-RAHMAN SZ, SALAMA SA, AU WW, HAMADA FA: Role of polymorphic CYP2E1 and CYP2D6 genes in NNK-induced chromosome aberrations in cultured human lymphocytes. Pharmacogenetics (2000) 10:239-249. (Pubitemid 30242740)
44. AGÚNDEZ JAG, GALLARDO L, LEDESMA MC et al.: Functionally active duplications of the CYP2D6 gene are more prevalent among larynx and lung cancer patients. Oncology (2001) 61:59-63. (Pubitemid 32727589)
45. AGÚNDEZ JAG: Cytochrome P450 gene polymorphism and cancer. Curr. Drug Metab. (2004) 5:211-224.
46. TSUNEOKA Y, FUKUSHIMA K, MATSUO Y, ICHIKAWA Y, WATANABE Y: Genotype analysis of the CYP2C19 gene in the Japanese population. Life Sci. (1996) 59:1711-1715. (Pubitemid 26364515)
47. BENHAMOU S, BOUCHARDY C, DAYER P: Lung cancer risk in relation to mephenytoin hydroxylation activity. Pharmacogenetics (1997) 7:157-159. (Pubitemid 27261850)
48. SHI WX, CHEN SQ: Frequencies of poor metabolizers of cytochrome P450 2C19 in esophagus cancer, stomach cancer, lung cancer and bladder cancer in Chinese population. World J. Gastroenterol. (2004) 10:1961-1963.
49. KLOSE TS, BLAISDELL JA, GOLDSTEIN JA: Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. J. Biochem. Mol. Toxicol. (1999) 13:289-295. (Pubitemid 129705404)
50. KAMATAKI T, FUJITA K, NAKAYAMA K, YAMAZAKI Y, MIYAMOTO M, ARIYOSHI N: Role of human cytochrome P450 (CYP) in the metabolic activation of nitrosamine derivatives: application of genetically engineered Salmonella expressing human CYP. Drug Metab. Rev. (2002) 34:667-676. (Pubitemid 35006071)
51. RAUNIO H, HAKKOLA J, HUKKANEN J et al.: Expression of xenobiotic-metabolizing CYPs in human pulmonary tissue. Exp. Toxicol. Pathol. (1999) 51:412-417. (Pubitemid 29334377)
52. ANDERSON E: Cellular homeostasis and the breast. Maturitas (2004) 48(Suppl. 1):S13-S17. (Pubitemid 39141189)
53. CHEN S: Aromatase and breast cancer. Front. Biosci. (1998) 3:d922-d933.
54. BOLT HM, GÖBEL P: Formation of estrogens from androgens by human subcutaneous adipose tissue in vitro. Horm. Metab. Res. (1972) 4:312-313.
55. HOLMBERG L, ANDERSON H; HABITS STEERING AND DATA MONITORING COMMITTEES: HABITS (hormonal replacement therapy after breast cancer - is it safe?), a randomised comparison: trial stopped. Lancet (2004) 363(9407):453-455. (Pubitemid 38210063)
56. BOLT HM: Rifampicin, a keystone inducer of drug metabolism: from Herbert Remmers pioneering ideas to modern concepts. Drug Metab. Rev. (2004) 36(3-4):497-509. (Pubitemid 39456439)
57. JUSTENHOVEN C, HAMANN U, PESCH B et al.: ERCC2 Genotypes and a corresponding haplotype are linked with breast cancer risk in a German population. Cancer Epidemiol. Biomarkers Prev. (2004) 13(12):2059-2064. (Pubitemid 40054298)
58. RYLANDER-RUDQVIST T, WEDREN S, GRANATH F et al.: Cytochrome P450 1B1 gene polymorphisms and postmenopausal breast cancer risk. Carcinogenesis. (2003) 24(9):1533-1539. (Pubitemid 37160844)
59. MITRUNEN K, KATAJA V, ESKELINEN M et al.: Combined COMT and GST genotypes and hormone replacement therapy associated breast cancer risk. Pharmacogenetics. (2002) 12(1):67-72. (Pubitemid 34112244)
60. PARK SK, YIM DS, YOON KS et al.: Combined effect of GSTM1, GSTT1, and COMT genotypes in individual breast cancer risk. Breast Cancer Res. Treat. (2004) 88:55-62. (Pubitemid 39524445)
61. TSUCHIYA Y, NAKAJIMA M, KYO S, KANAYA T, INOUE M, YOKOI T: Human CYP1B1 is regulated by estradiol via oestrogen receptor. Cancer Res. (2004) 64(9):3119-3125. (Pubitemid 38581412)
62. HANNA IH, DAWLING S, ROODI N, GUENGERICH FP, PARL FF: Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in oestrogen hydroxylation activity. Cancer Res. (2000) 60(13):3440-3444. (Pubitemid 30482162)
63. IVERSON SL, SHEN L, ANLAR N, BOLTON JL: Bioactivation of estrone and its catechol metabolites to quinoidglutathione conjugates in rat liver microsomes. Chem. Res. Toxicol. (1996) 9(2):492-499.
64. BOLT HM, KAPPUS H: Irreversible binding of ethynyl-estradiol to protein and nucleic acids as catalyzed by rat liver microsomes and mushroom tyrosinase. J. Steroid Biochem. (1974) 5:179-184.
65. HACHEY DL, DAWLING S, ROODI N, PARL FF: Sequential action of Phase I and II enzymes cytochrome P450 1B1 and glutathione S-transferase P1 in mammary oestrogen metabolism. Cancer Res. (2003) 63(23):8492-8499. (Pubitemid 37549506)
66. DAWLING S, HACHEY DL, ROODI N, PARL FF: In vitro model of mammary oestrogen metabolism: structural and kinetic differences between catechol oestrogens 2- and 4-hydroxyestradiol. Chem. Res. Toxicol. (2004) 17(9):1258-1264. (Pubitemid 39265882)
67. DAWLING S, ROODI N, PARL FF: Methoxyoestrogens exert feedback inhibition on cytochrome P450 1A1 and 1B1. Cancer Res. (2003) 63(12):3127-3132. (Pubitemid 36735863)
68. PARKIN DM: International variation. Oncogene (2004) 23:6329-6340. (Pubitemid 39272833)
69. BRAUERS A, MANEGOLD E, BUETTNER R, BARON JM, MERK HF, JAKSE G: Cytochrome P450 isoenzyme mRNA expression pattern in human urinary bladder malignancies and normal urothelium. Cancer Detect. Prev. (2000) 24:356-363.
70. IMAOKA S, YONEDA Y, MATSUDA T, DEGAWA M, FUKUSHIMA S, FUNAE Y: Mutagenic activation of urinary bladder carcinogens by CYP4B1 and the presence of CYP4B1 in bladder mucosa. Biochem. Pharmacol. (1997) 54:677-683. (Pubitemid 27404627)
71. DEGEN GH, SCHLATTJAN JH, MAHLER S, FOLLMANN W, GOLKA K: Comparative metabolic activation of benzidine and N-acetylbenzidine by prostaglandin H synthase. Toxicol. Lett. (2004) 151:135-142. (Pubitemid 38739035)
72. WOLF A, KUTZ A, PLÖTTNER S et al.: The effect of benzo(a)pyrene on porcine urinary bladder epithelial cells analyzed for the expression of selected genes and cellular toxicological endpoints. Toxicology (2005) 207:255-269. (Pubitemid 39642841)
73. IMAOKA S, YONEDA Y, SUGIMOTO T et al.: CYP4B1 is a possible risk factor for bladder cancer in humans. Biochem. Biophys. Res. Commun. (2000) 277:776-780.
74. VAZIRI SA, HUGHES NC, SAMPSON H, DARLINGTON G, JEWETT MA, GRANT DM: Variation in enzymes of arylamine procarcinogen biotransformation among bladder cancer patients and control subjects. Pharmacogenetics (2001) 11:7-20. (Pubitemid 32108657)
75. GAGO-DOMINGUEZ M, BELL DA, WATSON MA et al.: Permanent hair dyes and bladder cancer: risk modification by cytochrome P4501A2 and Nacetyltransferases 1 and 2. Carcinogenesis (2003) 24:483-489. (Pubitemid 36432644)
76. LEE SW, JANG IJ, SHIN SG et al.: CYP1A2 activity as a risk factor for bladder cancer. J. Korean Med. Sci. (1994) 9:482-489.
77. IMAOKA S, YONEDA Y, SUGIMOTO T et al.: Androgen regulation of CYP4B1 responsible for mutagenic activation of bladder carcinogens in the rat bladder: detection of CYP4B1 mRNA by competitive reverse transcriptionpolymerase chain reaction. Cancer Lett. (2001) 166:119-123. (Pubitemid 32322656)
78. RYLANDER T, NEVE EP, INGELMAN-SUNDBERG M, OSCARSON M: Identification and tissue distribution of the novel human cytochrome P450 2S1 (CYP2S1). Biochem. Biophys. Res. Commun. (2001) 281:529-535. (Pubitemid 32928187)
79. BROCKMÖLLER J, CASCORBI I, KERB R, ROOTS I: Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res. (1996) 56:3915-3925. (Pubitemid 26284739)
80. ANWAR WA, ABDEL-RAHMAN SZ, EL-ZEIN RA, MOSTAFA HM, AU WW: Genetic polymorphism of GSTM1, CYP2E1 and CYP2D6 in Egyptian bladder cancer patients. Carcinogenesis (1996) 17:1923-1929. (Pubitemid 26325384)
81. CHINEGWUNDOH FI, KAISARY AV: Polymorphism and smoking in bladder carcinogenesis. Br. J. Urol. (1996) 77:672-675. (Pubitemid 27402273)
82. KOMHOFF M, GUAN Y, SHAPPELL HW et al.: Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am. J. Pathol. (2000) 157:29-35. (Pubitemid 30641721)
83. GRUBBS CJ, LUBET RA, KOKI AT et al.: Celecoxib inhibits N-butyl-N-(4- hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res. (2000) 60:5599-5602.
84. KANG S, KIM YB, KIM MH et al.: Polymorphism in the nuclear factor kappa- B binding promoter region of cyclooxygenase-2 is associated with an increased risk of bladder cancer. Cancer Lett. (2005) 217:11-16. (Pubitemid 39642861)
85. BROCKMÖLLER J, KAISER R, KERB R, CASCORBI I, JAEGER V, ROOTS I: Polymorphic enzymes of xenobiotic metabolism as modulators of acquired P53 mutations in bladder cancer. Pharmacogenetics (1996) 6:535-545.
86. BRENNAN P, BOFFETTA P: Mechanistic considerations from the molecular epidemiology of head and neck cancer. In: Mechanisms of Carcinogenesis. IARC Scientific Publications (2004) 157:393-414.
87. NIMURA Y, YOKOYAMA S, FUJIMORI M et al.: Genotyping of the CYP1A1 and GSTM1 genes in esophageal carcinoma patients with special reference to smoking. Cancer (1997) 80:852-857. (Pubitemid 27360465)
88. OLSHAN AF, WEISSLER MC, WATSON MA, BELL DA: GSTM1, GSTT1, GSTP1, CYP1A1, and NAT1 polymorphisms, tobacco use, and the risk of head and neck cancer. Cancer Epidemiol. Biomarkers Prev. (2000) 9:185-191. (Pubitemid 30111942)
89. MCWILLIAMS JE, EVANS AJ, BEER TM et al.: Genetic polymorphisms in head and neck cancer risk. Head Neck (2000) 22:609-617. (Pubitemid 30663077)
90. SREELEKHA TT, RAMADAS K, PANDEY M, THOMAS G, NALINAKUMARI KR, PILLAI MR: Genetic polymorphism of CYP1A1, GSTM1 and GSTT1 genes in Indian oral cancer. Oral Oncol. (2001) 37:593-598. (Pubitemid 32889622)
91. MORITA S, YANO M, TSUJINAKA T et al.: Genetic polymorphisms of drugmetabolizing enzymes and susceptibility to head-and-neck squameous-cell carcinoma. Int. J. Cancer (1999) 80:685-688. (Pubitemid 29066278)
92. GRONAU S, KOENIG-GREGER D, JERG M, REICHELMANN H: Gene polymorphisms in detoxification enzymes as susceptibility factor for head and neck cancer? Otolaryngol. Head Neck Surg. (2003) 128:674-680. (Pubitemid 41123130)
93. GEISLER SA, OLSHAN AF: GSTM1, GSTT1, and the risk of squamous cell carcinoma of the head and neck: a minireview. Am. J. Epidemiol (2001) 154:95-105. (Pubitemid 32643123)
94. TAN W, SONG N, WANG GQ et al.: Impact of genetic polymorphisms in cytochrome P450 2E1 and glutathione S-transferases M1, T1, and P1 on susceptibility to esophageal cancer among high-risk individuals in China. Cancer Epidemiol. Biomarkers Prev. (2000) 9:551-556. (Pubitemid 30396175)
95. TAN W, CHEN GF, XING DY, SONG CY, KADLUBAR FF, LIN DX: Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population. Int. J. Cancer (2001) 95:96-101. (Pubitemid 32187080)
96. CAMUS A-M, GENESTE O, HONKAKOSKI P et al.: High variability of nitrosamine metabolism among individuals: role of cytochromes P450 2A6 and 2E1 in the dealkylation of N-nitrosodimethylamine and N-nitrosodiethylamine in mice and humans. Mol. Carcinogen. (1993) 7:268-275. (Pubitemid 23200893)
97. CHEN SC, ZHOU L, DING X, MIRVISH SS: Depentylation of the rat esophageal carcinogen, methyl-Npentylnitrosamine, by microsomes from various human and rat tissues and by cytochrome P450 2A3. Drug Metab. Dispos. (2001) 29:1221-1228. (Pubitemid 32800235)
98. NEUHAUS T, KO YD, LORENZEN K et al.: Association of cytochrome P450 2E1 polymorphisms and head and neck squameous cell cancer. Toxicol. Lett. (2004) 151:273-282. (Pubitemid 38739050)
99. KO Y, ABEL J, HARTH V et al.: Association of CYP1B1 codon 432 mutant allele in head and neck squamous cell cancer is reflected by somatic mutations of p53 in tumor tissue. Cancer Res. (2001) 61:4398-4404. (Pubitemid 32685766)
100. WEBER A, TANNAPFEL A, WITTEKIND C, BOOTZ F: Carcinogeninduced site-specific mutagenesis and genetic susceptibility in squamous cell carcinoma of the head and neck. Onkologie (2002) 25:8-13. (Pubitemid 34224987)
101. BANASZEWSKI J, SZEMEJA Z, SZYFTER W, SZYFTER K, BARANCZEWSKI P, MÖLLER L: Analysis of aromatic DNA adducts in laryngeal biopsies. Eur. Arch. Otorhinolaryngol. (2000) 257:149-153. (Pubitemid 30218977)
102. DEGAWA M, STERN SJ, MARTIN MV et al.: Metabolic activation and carcinogen- DNA adduct detection in human larynx. Cancer Res. (1994) 15:4915-4919. (Pubitemid 24289421)
103. BADAWI AF, STERN SJ, LANG NP, KADLUBAR FF: Cytochrome P450 and acetyltransferase expression as biomarkers of carcinogen-DNA adduct levels and human cancer suceptibility. Prog. Clin. Biol. Res. (1996) 395:109-140.
104. SUTTER TR, TANG YM, HAYES CL et al.: Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. J. Biol. Chem. (1994) 269:13092-13099. (Pubitemid 24206069)
105. MURRAY GI, TAYLOR MC, MCFADYEN MC et al.: Tumor-specific expression of cytochrome P 450 CYP1B1. Cancer Res. (1997) 57:3026-3031. (Pubitemid 27315056)
106. MURRAY GI, MELVIN WT, GREENLEE WF, BURKE MD: Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1. Annu. Rev. Pharmacol. Toxicol. (2001) 41:297-316. (Pubitemid 32390115)
107. BAILEY LR, ROODI N, DUPONT WD, PARL FF: Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res. (1998) 58:5038-5041 [Erratum (1999) Cancer Res. 59:1388]. (Pubitemid 28521155)
108. MCLELLAN RA, OSCARSON M, HIDESTRAND M et al.: Characterization and functional analysis of two common human cytochrome P450 1B1 variants. Arch. Biochem. Biophys. (2000) 378:175-181. (Pubitemid 30350478)
109. LI DN, SEIDEL A, PRITCHARD MP, WOLF CR, FRIEDBERG T: Polymorphisms in P450 CYP1B1 affect the conversion of estradiol to the potentially carcinogenic metabolite 4-hydroxyestradiol. Pharmacogenetics (2000) 10:343-353. (Pubitemid 30345182)
110. BRÜNING T, ABEL J, KOCH B et al.: Real-time PCR-analysis of the cytochrome P450 1B1 codon 432-polymorphism. Arch. Toxicol. (1999) 73:427-430. (Pubitemid 30010243)
111. SHIMADA T, HAYES CL, SPINK DC et al.: Activation of chemically diverse procarcinogens by human cytochrome P450 1B1. Cancer Res. (1996) 56:2979-2984. (Pubitemid 26199741)
112. CRESPI CL, PENMAN BW, STEINER DT, SMITH T, YANG CS, SUTTER TR: Development of a human lymphoblastoid cell line constitutively expressing human CYP1B1 cDNA: substrate specificity with model substrates and promutagens. Carcinogenesis (1997) 12:83-89. (Pubitemid 27153695)
113. SPINK DC, HAYES CL, YOUNG NR et al.: The effects of 2,3,7,8- tetrachlorodibeno-p-dioxin on estrogen metabolism in MCF-7 breast cancer cells: evidence for induction of a novel 17 betaestradiol 4-hydroxylase. J. Steroid Biochem. Molec. Biol. (1994) 51:251-258.
114. HAYES CL, SPINK DC, SPINK BC, CAO JQ, WALKER NJ, SUTTER TR: 17β-Estradiol hydroxylation catalyzed by human cytochrome mP450 1B1. Proc. Natl. Acad. Sci. USA (1996) 93:9776-9781. (Pubitemid 26296685)
115. KIM JH, STANSBURY KH, WALKER NJ, TRUSH MA, STRICKLAND PT, SUTTER TR: Metabolism of benzo(a)pyrene and benzo(a)pyrene-7,8-diol by human cytochrome P450 1B1. Carcinogenesis (1998) 19:1847-1853 [Erratum, 1999: Carcinogenesis 20:515]. (Pubitemid 28474651)
116. HEIDEL SM, MACWILLIAMS PS, BAIRD WM et al.: Cytochrome P4501B1 mediates induction of bone marrow cytotoxicity and preleukemia cells in mice treated with 7,12- dimethylbenz(a)anthracene. Cancer Res. (2000) 60:3454-3460. (Pubitemid 30482164)
117. LUCH A, COFFING SL, TANG YM et al.: Stable expression of human cytochrome P450 1B1 in V79 Chinese hamster cells and metabolically catalyzed DNA adduct formation of dibenzo[a,l]pyrene. Chem. Res. Toxicol. (1998) 11:686-695. (Pubitemid 28285594)
118. LUCH A, SCHOBER W, SOBALLA VJ et al.: Metabolic activation of dibenzo[a,l]pyrene by human cytochrome P450 1A1 and P450 1B1 expressed in V79 Chinese hamster cells. Chem. Res. Toxicol. (1999) 12:353-364. (Pubitemid 29193912)
119. SHIMADA T, WATANABE J, KAWAJIRI K et al.: Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis (1999) 20:1607-1613. (Pubitemid 29385452)
120. SHIMADA T, WATANABE J, INOUE K, GUENGERICH FP, GILLAM EM: Specificity of 17beta-oestradiol and benzo[a]pyrene oxidation by polymorphic human cytochrome P4501B1 variants substituted at residues 48, 119 and 432. Xenobiotica (2001) 31:163-176. (Pubitemid 32635344)
121. KISS I, SANDOR J, PAJKOS G, BOGNER B, HEGEDUS G, EMBER I: Colorectal cancer risk in relation to genetic polymorphism of cytochrome P450 1A1, 2E1, and glutathione-S-transferase M1 enzymes. Anticancer Res. (2000) 20:519-522. (Pubitemid 30189713)
122. YIN PH, LEE HC, CHAU GY et al.: Polymorphisms of estrogen-metabolizing genes and risk of hepatocellular carcinoma in Taiwan females. Cancer Lett. (2004) 212:195-201.
123. HAN XM, OU-YANG DS, LU PX et al.: Plasma caffeine metabolite ratio (17X/ 137X) in vivo associated with G-2964A and C734A polymorphisms of human CYP1A2. Pharmacogenetics (2001) 11:429-435.
124. WOJNOWSKI L, TURNER PC, PEDERSEN B et al.: Increased levels of aflatoxin-albumin adducts are associated with CYP3A5 polymorphisms in The Gambia, West Africa. Pharmacogenetics (2004) 14:691-700. (Pubitemid 39411269)
125. LONGUEMAUX S, DELOMENIE C, GALLOU C et al.: Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes. Cancer Res. (1999) 59:2903-2908. (Pubitemid 29283130)
126. SASAKI M, TANAKA Y, OKINO ST et al.: Polymorphisms of the CYP1B1 gene as risk factors for human renal cell cancer. Clin. Cancer Res. (2004) 10:2015-2019. (Pubitemid 38375561)
127. FARKER K, LEHMANN MH, OELSCHLAGEL B et al.: Impact of CYP2E1 genotype in renal cell and urothelial cancer patients. Exp. Toxicol. Pathol. (1998) 50:425-431. (Pubitemid 28439494)
128. http://www.icgeb.trieste.it/~p450srv/new/ p450.html
129. http://www.imm.ki.se/CYPalleles
130. http://www.imm.ki.se/CYPalleles/cyp1b1.htm